Get the Weekly Intelligence Brief — top committee picks every Sunday.
WAY · NASDAQ · STOCK

Waystar Holding (WAY) Stock Analysis

Healthcare Updated October 14, 2026
$28.04
52W $17.26 – $40.35
58/100
$5.04B
36.5
0.07
AI Committee Verdict
Buy
58/100
Conviction: Moderate · 60% agreement · 5 analysts
+0.4%
-14.6%
0.03:1
Moderate
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.

Is WAY Bullish or Bearish?

Bullish. Innellis AI committee rates Waystar Holding Corp. (WAY) Buy with a composite score of 58/100 , based on 5 analysts with 60% agreement. Last updated October 14, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +16.75 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -3.25 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — 2 existing position pair(s) are highly correlated already. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • EPS growing 46.4% YoY — Growth
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • P/E of 37.9 is moderate-to-rich — Value
  • ROE of only 3.6% -- cheap may mean cheap for a reason — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 14, 2026
Overall Committee Score
58/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 44%
of 192 Healthcare peers
Value Analyst neutral
49 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 37.9 is moderate-to-rich
Growth Analyst bullish
62 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 46.4% YoY
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager bearish
35 / 100 · Low confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Investment Thesis Evolution

Committee score weakened from 61.2 to 58.2.

Analyst-level changes:
  • Macro Analyst: score 80->65 (-15).
  • Portfolio Manager: score 30->35 (+5).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-10-13 to 2026-10-14 (1 day apart).

Technical Analysis

RSI (14)
63.6
Neutral
MACD Histogram
0.089
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$22.97
Resistance
$27.00
Bollinger %B
0.88
Inside Bands
Price vs Moving Averages
EMA 9
$26.31 Above
EMA 21
$25.86 Above
EMA 50
$25.02 Above
EMA 200
$25.66 Above

Fundamental Analysis

Valuation
71
Growth
50
Profitability
47
Financial Health
94
Cash Flow
70
Valuation
P/E Ratio 36.5×
P/B Ratio 1.27×
PEG Ratio 0.83
Dividend Yield 0.00%
52W High $40.35
52W Low $17.26
Quality & Growth
ROE 289.0%
ROA 193.8%
Gross Margin 6910.6%
Operating Margin 2287.0%
Revenue Growth YoY —
Debt / Equity 0.37
AI Fundamental Assessment
P/E ratio of 36.5 (rich relative to a 15-40x range); Price-to-book of 1.3x; PEG ratio of 0.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 2.9%; Return on assets of 1.9%; Net margin of 11.2%; Gross margin of 69.1%; Current ratio of 1.85 (healthy short-term liquidity); Debt-to-equity of 0.37; Free cash flow per share is positive (1.28); Most recent quarter beat estimates by 7.4%; 2 consecutive earnings beats; EPS growth decelerating (+16.7% -> +2.4% QoQ); Analyst estimates flat over recent quarters
Get the Full WAY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime